Aptilon unveils new sales force tool

Aptilon announced the availability of an expanded set of tools that enables biopharmaceutical companies to increase access to valuable, high-prescribing physicians.

By combining new field-tested, rep-enabled tools with its established capabilities, Aptilon now offers biopharmaceutical sales representatives and medical science liaisons new and more effective ways to interact with hard-to-see physicians.

Aptilon's new services allow companies and their field reps to educate target physicians about their therapies, services and clinical research through five complementary options, including: remote live video details  that allows field sales to deliver Aptilon's AxcelRx live video detail sessions via their laptop or TabletPC from any location; call center live video details; self-guided activities; in-office contacts; and follow-up activities with new linkage tools including Aptilon's new Rep eMail capability enabling the field representative to send rapid, effective, personalized and regulatory-compliant follow-up emails to targeted physicians.

Whether a physician engaged with the company via an in-office detail or an Internet-based interaction, Aptilon's Rep eMail service allows for follow-up dialogue between the representative and the physician.

Each Rep eMail includes links that allow a physician to initiate an on-demand interaction with their rep at their convenience.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.